Source: CNN Author: Val Willingham (CNN) -- A vaccine that could help people stop smoking is showing promise in early clinical trials, researchers announced this week at a national meeting of addiction specialists. The vaccine is designed to stimulate the immune system to generate antibodies that would latch on to nicotine in a smoker's body and prevent it from ever entering the brain. The vaccine maker, Nabi Biopharmaceuticals, reported that those who responded best to NicVAX in earlier testing had been able to quit smoking for three times longer than those in the placebo group, with data from 19 to 26 weeks, and then for 12 months. These are considered statistically significant results and superior to the testing results of Zyban and Chantix, prescription medications already approved to help smokers over the age of 18 quit, Nabi officials told the National Institute on Drug Abuse conference in Albuquerque, New Mexico. In addition, those whose bodies responded most effectively to NicVAX cut the number of cigarettes smoked, from a baseline of 20 cigarettes per day to 10 cigarettes per day. Those who took the vaccine experienced few side effects, said Dr. Raafat Fahim, president and CEO of Nabi Biopharmaceuticals. In 2009, Zyban and Chantix were ordered by the Food and Drug Administration to carry "black box" warnings of the risk of depression and suicidal thoughts. Nabi began the first phase III trials for NicVAX last November, enrolling 1,000 people. In March, a second phase III trial began with another 1,000 participants. [...]